Dose-ranging safety and efficacy study of topical creams containing API 31510 for the treatment of in situ cutaneous squamous cell carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
- 24 Jul 2012 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from not yet recruiting to not stated.
- 07 Mar 2008 New trial record.